AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12635577 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene modifiers (LM)
Number of subjects: 960
Study 12635577 — intervention group
Group type: COMPARATOR
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 960
Study 10694338 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 462
Study 10694338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 462
Study 10694338 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteinuria at baseline
Number of subjects: 462
Study 9121313 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide and halothane
Number of subjects: 97
Study 9121313 — intervention group
Group type: COMPARATOR
Intervention: Halothane alone
Number of subjects: 97
Study 8452163 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fleroxacin (200 mg once daily)
Number of subjects: 296
Study 8452163 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fleroxacin (400 mg once daily)
Number of subjects: 296
Study 8452163 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin (400 mg twice daily)
Number of subjects: 296
Study 3535872 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 0.5%
Number of subjects: 103
Study 3535872 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolmetin 2%
Number of subjects: 103
Study 3535872 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle only)
Number of subjects: 103
Study 31482510 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac 0.09%
Number of subjects: 76
Study 31482510 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 0.1%
Number of subjects: 76
Study 30590128 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUD
Number of subjects: 39
Study 30590128 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 26163338 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry concentrate (30 mL)
Number of subjects: 12
Study 26163338 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorency tart cherry concentrate (60 mL)
Number of subjects: 12
Study 26163338 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PCA and VA
Number of subjects: 12
Study 25134285 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (400 ug, 6 and 12 hours prior to surgery)
Number of subjects: 120
Study 25134285 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 ug, 6 and 12 hours prior to surgery)
Number of subjects: 120
Study 25134285 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal misoprostol (400 ug, 6 and 12 hours prior to surgery)
Number of subjects: 120
Study 25134285 — intervention group
Group type: COMPARATOR
Intervention: Control group (no misoprostol)
Number of subjects: 120
Study 22915652 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant 125 mg on day 3 and 80 mg per day on days 4 through 7
Number of subjects: 69
Study 22915652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 22915652 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 69
Study 20081570 — intervention group
Group type: EXPERIMENTAL
Intervention: Askina Calgitrol Ag
Number of subjects: 42
Study 20081570 — intervention group
Group type: COMPARATOR
Intervention: Algosteril
Number of subjects: 42
Study 17293018 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-C. difficile whey protein concentrate (anti-CD WPC)
Number of subjects: 77
Study 17293018 — intervention group
Group type: COMPARATOR
Intervention: Regular whey protein concentrate
Number of subjects: 77
Study 16214734 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized genotypic resistance testing
Number of subjects: 55
Study 16214734 — intervention group
Group type: COMPARATOR
Intervention: No testing (Control)
Number of subjects: 55
Study 11533599 — intervention group
Group type: EXPERIMENTAL
Intervention: PVAG
Number of subjects: 142
Study 11533599 — intervention group
Group type: COMPARATOR
Intervention: ePTFE
Number of subjects: 142
Study 9514186 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL 100,240 (doses: 1.56 mg, 6.25 mg, 25 mg, 3.13 mg, 12.5 mg, 50 mg)
Number of subjects: 8
Study 9514186 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL 100,240 (doses: 3.125 mg, 25 mg, 50 mg)
Number of subjects: 8
Study 9514186 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL 100,240
Number of subjects: 8
Study 9514186 — intervention group
Group type: COMPARATOR
Intervention: Exogenous angiotensin II challenge
Number of subjects: 8
Study 7513406 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic defibrillation waveform
Number of subjects: 30
Study 7513406 — intervention group
Group type: COMPARATOR
Intervention: Monophasic defibrillation waveform
Number of subjects: 30
Study 3198545 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape with behavior rehearsal
Number of subjects: 0
Study 3198545 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape only
Number of subjects: 0
Study 3198545 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard safety program
Number of subjects: 0
Study 3198545 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 0
Study 31843995 — intervention group
Group type: EXPERIMENTAL
Intervention: SUL-DUR (1 g/1 g intravenously every 6 hours for 7 days)
Number of subjects: 80
Study 31843995 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous every 6 hours for 7 days)
Number of subjects: 80
Study 31843995 — intervention group
Group type: EXPERIMENTAL
Intervention: SUL-DUR with IMI background therapy
Number of subjects: 80
Study 29978593 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-initiated follow up
Number of subjects: 156
Study 29978593 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based follow up
Number of subjects: 156
Study 26370102 — intervention group
Group type: EXPERIMENTAL
Intervention: Taoist Qigong training for 1 month
Number of subjects: 43
Study 26370102 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 43
Study 25246392 — intervention group
Group type: EXPERIMENTAL
Intervention: Tedizolid 200 mg once daily for 6 days
Number of subjects: 0
Study 25246392 — intervention group
Group type: COMPARATOR
Intervention: Linezolid 600 mg twice daily for 10 days
Number of subjects: 0
Study 22777222 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1.2%/BPO 2.5% gel
Number of subjects: 337
Study 22777222 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 337
Study 20598271 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults with long preparatory interval
Number of subjects: 0
Study 20598271 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults with short preparatory interval
Number of subjects: 0
Study 20598271 — intervention group
Group type: COMPARATOR
Intervention: Younger adults
Number of subjects: 0
Study 20598271 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 0
Study 18052567 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 145
Study 18052567 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 145
Study 18052567 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 145
Study 16354458 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combined hormone replacement therapy (ccHRT; Indivina, Orion Pharma, Finland)
Number of subjects: 0
Study 16354458 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched women from Finnish population health surveys)
Number of subjects: 0
Study 12079031 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 111
Study 12079031 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 111
Study 10644486 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal pacing with 5-mA amplitude and 200-ms pulse width
Number of subjects: 24
Study 10644486 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal pacing in study group
Number of subjects: 24
Study 10644486 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pacing)
Number of subjects: 24
Study 8777665 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed heel
Number of subjects: 57
Study 8777665 — intervention group
Group type: COMPARATOR
Intervention: Unwarmed heel
Number of subjects: 57
Study 1998863 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasonography
Number of subjects: 99
Study 1998863 — intervention group
Group type: COMPARATOR
Intervention: Palpation of the liver
Number of subjects: 99
Study 1998863 — intervention group
Group type: COMPARATOR
Intervention: Preoperative abdominal ultrasonography
Number of subjects: 99
Study 1998863 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography scanning
Number of subjects: 99
Study 6398158 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozic (100 mg/day)
Number of subjects: 56
Study 6398158 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozic (300 mg/day)
Number of subjects: 56
Study 6398158 — intervention group
Group type: COMPARATOR
Intervention: D-penicillamine (500 mg/day)
Number of subjects: 56
Study 6398158 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (up to 3.6 g/day)
Number of subjects: 56
Study 30861606 — intervention group
Group type: EXPERIMENTAL
Intervention: CLCA-ESD
Number of subjects: 50
Study 30350779 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide treatment (CWT) for 4 years
Number of subjects: 14620
Study 30350779 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based treatment (SBT) for 2 years followed by 2 years without treatment (holiday)
Number of subjects: 14620
Study 30350779 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 years of SBT
Number of subjects: 14620
Study 30350779 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 years of SBT combined with 2 years of treatment holiday
Number of subjects: 14620
Study 26761518 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IL-12 (50 μg) with HIV MAG pDNA by IM-EP
Number of subjects: 62
Study 26761518 — intervention group
Group type: COMPARATOR
Intervention: Any vaccine arm
Number of subjects: 62
Study 24450538 — intervention group
Group type: EXPERIMENTAL
Intervention: Armodafinil 150 mg
Number of subjects: 383
Study 22508813 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg two times per day)
Number of subjects: 510
Study 22508813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 510
Study 19464421 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 100
Study 19464421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 17251802 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacrimal punctum occlusion (punctum plug in upper and lower puncta)
Number of subjects: 20
Study 17251802 — intervention group
Group type: COMPARATOR
Intervention: Control eye (not occluded)
Number of subjects: 20
Study 15970809 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate therapy until the onset of diuresis (urine output >100 mL/hr for 2 consecutive hours)
Number of subjects: 98
Study 15970809 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate therapy for 24 hours (control group)
Number of subjects: 98
Study 11552905 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitor b.d. (omeprazole 20 mg or lansoprazole 30 mg)
Number of subjects: 105
Study 11552905 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor b.d. (omeprazole 20 mg or lansoprazole 30 mg) plus bedtime H2-blocker
Number of subjects: 105
Study 11552905 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime H2RA added to proton pump inhibitor b.d.
Number of subjects: 105
Study 9314118 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine (5 to 600 mg per day) for 4 weeks
Number of subjects: 17
Study 8365298 — intervention group
Group type: EXPERIMENTAL
Intervention: albuterol by metered dose inhaler (0.4 mg)
Number of subjects: 80
Study 8365298 — intervention group
Group type: COMPARATOR
Intervention: albuterol by wet nebulizer (2.5 mg)
Number of subjects: 80
Study 2427807 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 14
Study 3076999 — intervention group
Group type: EXPERIMENTAL
Intervention: RE7 (rifampicin and ethambutol daily)
Number of subjects: 501
Study 3076999 — intervention group
Group type: EXPERIMENTAL
Intervention: RE3 (rifampicin and ethambutol thrice weekly)
Number of subjects: 501
Study 3076999 — intervention group
Group type: EXPERIMENTAL
Intervention: REZ3 (rifampicin, ethambutol, and pyrazinamide for the first 3 months)
Number of subjects: 501
Study 3076999 — intervention group
Group type: EXPERIMENTAL
Intervention: REPt3 (rifampicin, ethambutol, and prothionamide for the first 3 months)
Number of subjects: 501
Study 30602406 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrete choice experiment (DCE) methodology
Number of subjects: 10
Study 30602406 — intervention group
Group type: EXPERIMENTAL
Intervention: DCE attributes identified
Number of subjects: 10
Study 30602406 — intervention group
Group type: EXPERIMENTAL
Intervention: Refinements made to DCE
Number of subjects: 10
Study 30602406 — intervention group
Group type: EXPERIMENTAL
Intervention: Final planned DCE execution
Number of subjects: 10
Study 28473924 — intervention group
Group type: EXPERIMENTAL
Intervention: Storytelling intervention (We Talk about Our Hypertension)
Number of subjects: 160
Study 28473924 — intervention group
Group type: COMPARATOR
Intervention: Didactic intervention
Number of subjects: 160
Study 25496927 — intervention group
Group type: EXPERIMENTAL
Intervention: Sterile elastic exsanguination tourniquet
Number of subjects: 311
Study 25496927 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic tourniquet
Number of subjects: 311
Study 23327355 — intervention group
Group type: COMPARATOR
Intervention: Supportive Listening (SL)
Number of subjects: 296
Study 23327355 — intervention group
Group type: COMPARATOR
Intervention: Pragmatic Rehabilitation (PR)
Number of subjects: 296
Study 23327355 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Number of subjects: 296
Study 21659893 — intervention group
Group type: EXPERIMENTAL
Intervention: β-alanine (4 g·d in powdered capsule form)
Number of subjects: 37
Study 21659893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 18076750 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent smoking cessation treatment
Number of subjects: 462
Study 18076750 — intervention group
Group type: COMPARATOR
Intervention: Delayed smoking cessation treatment
Number of subjects: 462
Study 17069590 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiotherapy followed by surgery (CRT group)
Number of subjects: 45
Study 17069590 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (Surgery group)
Number of subjects: 45
Study 15228924 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heroin treatment
Number of subjects: 0
Study 15228924 — intervention group
Group type: COMPARATOR
Intervention: Oral methadone
Number of subjects: 0
Study 10924606 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC-reduced platelet concentrates (PCs)
Number of subjects: 13
Study 10924606 — intervention group
Group type: COMPARATOR
Intervention: Standard platelet concentrates (S-PCs)
Number of subjects: 13
Study 9051367 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicultural community health worker (CHW) intervention
Number of subjects: 64
Study 9051367 — intervention group
Group type: COMPARATOR
Intervention: Non-CHW intervention
Number of subjects: 64
Study 9051367 — intervention group
Group type: EXPERIMENTAL
Intervention: Program completers
Number of subjects: 64
Study 8112444 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 10
Study 8112444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3456079 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (1000 mg per square meter) infused over 24 hours
Number of subjects: 108
Study 30855231 — intervention group
Group type: EXPERIMENTAL
Intervention: HypoDetect (Hypoglycemia Detector) using logistic regression with cost-sensitive learning
Number of subjects: 3000
Study 30855231 — intervention group
Group type: COMPARATOR
Intervention: Baseline systems without cost-sensitive learning
Number of subjects: 3000
Study 28903955 — intervention group
Group type: EXPERIMENTAL
Intervention: Rare meat (RM) cooked at 55°C for 5 min
Number of subjects: 10
Study 28903955 — intervention group
Group type: COMPARATOR
Intervention: Fully cooked meat (FCM) cooked at 90°C for 30 min
Number of subjects: 10
Study 25727851 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 11
Study 25727851 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 11
Study 25727851 — intervention group
Group type: EXPERIMENTAL
Intervention: FeNO levels
Number of subjects: 11
Study 23178661 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuling capsule
Number of subjects: 186
Study 23178661 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study 21212667 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 184
Study 21212667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study 18763030 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicle rupture evident by transvaginal ultrasonography
Number of subjects: 417
Study 18763030 — intervention group
Group type: COMPARATOR
Intervention: No follicle rupture evident
Number of subjects: 417
Study 16968848 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan-based treatment regimen
Number of subjects: 8831
Study 16968848 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-based treatment regimen
Number of subjects: 8831
Study 12543279 — intervention group
Group type: EXPERIMENTAL
Intervention: Dawn-dusk simulation (DDS) light therapy
Number of subjects: 13
Study 12543279 — intervention group
Group type: COMPARATOR
Intervention: Dim red light (placebo)
Number of subjects: 13
Study 11239099 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient commitment with case management services and outpatient treatment
Number of subjects: 331
Study 11239099 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended outpatient commitment
Number of subjects: 331
Study 11239099 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained outpatient commitment combined with intensive outpatient treatment
Number of subjects: 331
Study 11239099 — intervention group
Group type: COMPARATOR
Intervention: Control group (no outpatient commitment)
Number of subjects: 331
Study 9309626 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 72
Number of subjects: 6
Study 9309626 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 144
Number of subjects: 6
Study 9309626 — intervention group
Group type: COMPARATOR
Intervention: C 72
Number of subjects: 6
Study 8312677 — intervention group
Group type: EXPERIMENTAL
Intervention: perindopril
Number of subjects: 44
Study 8312677 — intervention group
Group type: EXPERIMENTAL
Intervention: ketanserin
Number of subjects: 44
Study 2906346 — intervention group
Group type: EXPERIMENTAL
Intervention: Triphasic combination of gestodene and ethinyl estradiol
Number of subjects: 2298
Study 2906346 — intervention group
Group type: COMPARATOR
Intervention: Low-dose triphasic combination of levonorgestrel and ethinyl estradiol
Number of subjects: 2298
Study 31771942 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquamin (800 mg of calcium per day)
Number of subjects: 30
Study 31771942 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 30
Study 31771942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 31771942 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquamin
Number of subjects: 30
Study 31771942 — intervention group
Group type: COMPARATOR
Intervention: Calcium
Number of subjects: 30
Study 28937546 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Unilateral ECT (RUL)
Number of subjects: 82
Study 28937546 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifrontal ECT (BF)
Number of subjects: 82
Study 28937546 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitemporal ECT (BT)
Number of subjects: 82
Study 28937546 — intervention group
Group type: COMPARATOR
Intervention: Cognitive outcomes
Number of subjects: 82
Study 27942876 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Extraperitoneal Repair (TEP)
Number of subjects: 50
Study 27942876 — intervention group
Group type: COMPARATOR
Intervention: Stoppa Repair
Number of subjects: 50
Study 25733584 — intervention group
Group type: EXPERIMENTAL
Intervention: GMI-1070
Number of subjects: 76
Study 25733584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 23159276 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine (4 mg daily for 4 weeks with an optional increase to 8 mg)
Number of subjects: 963
Study 23159276 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 963
Study 21385509 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (2 x 5 mg orally)
Number of subjects: 19
Study 21385509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 18171453 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg methylphenidate, parent training programme
Number of subjects: 16
Study 18171453 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg methylphenidate, parent support programme
Number of subjects: 16
Study 18171453 — intervention group
Group type: COMPARATOR
Intervention: placebo medication, parent training
Number of subjects: 16
Study 18171453 — intervention group
Group type: COMPARATOR
Intervention: placebo medication, parent support
Number of subjects: 16
Study 17345818 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (Fosamax)
Number of subjects: 187
Study 17345818 — intervention group
Group type: COMPARATOR
Intervention: Calcium and Vitamin D
Number of subjects: 187
Study 17345818 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 187
Study 14629104 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with sodium porfimer administered 48 hours before photoradiation.
Number of subjects: 0
Study 14629104 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 0